BridgeBio Pharma is preparing for what could become a major expansion of its commercial portfolio, with three pipeline programs moving into active regulatory review and the company positioning its balance sheet to support multiple launches simultaneously.
BridgeBio said all three of its planned New Drug Applications have now been submitted to the FDA. BBP-418 for limb-girdle muscular dystrophy type 2I/R9 received Priority Review with a November 27, 2026 PDUFA date. Encaleret for autosomal dominant hypocalcemia type 1 also received Priority Review, with a May 8, 2027 PDUFA date. Oral infigratinib for achondroplasia has also been submitted, with a potential U.S. launch targeted for mid-2027.
The company is preparing its commercial infrastructure ahead of those potential approvals. BridgeBio said its neuromuscular field teams have already been hired, trained and deployed across medical, commercial and market access functions for BBP-418. It is also increasing disease awareness in advance of potential launches, including identifying more than 2,200 unique ADH patients under the dedicated ICD-10 code.
BridgeBio ended June with $720.2 million in cash, cash equivalents and marketable securities, before accounting for a $1 billion preferred equity financing that closed July 1. Management said the additional financing provides the balance sheet needed to pursue all three launches without reducing investment in the company’s development pipeline.
BridgeBio’s existing commercial product, Attruby, generated $222.4 million of U.S. net product revenue during the second quarter. Total quarterly revenue reached $243.7 million.
KEY QUOTES:
“This was the quarter all three of our pipeline programs, BBP-418, encaleret, and infigratinib, moved from data into active regulatory review, with our first PDUFA date now set for November 27, 2026, which is a level of strategic execution and discipline I’m proud of. Finally, with the $1 billion preferred equity financing we completed, we have a balance sheet sized to run all three launches at full strength, without diverting resources from the development engine that produced them.”
Neil Kumar, Ph.D., Co-Founder and CEO of BridgeBio
